Latest PCA3 Stories
-- 300 patient US pilot study shows MiCheck(TM) test has 85% specificity - compared to 40% for existing PSA technology SYDNEY, April 20, 2015 /PRNewswire/ -- A NEW
Opportunities Being Developed While the Situation with the PCA3 Prostate Cancer Test is Being Resolved QUEBEC CITY, Oct. 30, 2014 /PRNewswire/ - DiagnoCure, Inc.
Additional Tests to Demonstrate the Importance of Utilizing Multiple Biological Pathways to Provide Patients, Physicians with Confidence to Make Educated Treatment Decisions CAMBRIDGE,
LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Providing Corporate Update on Key Projects QUEBEC CITY, Jan. 16, 2014 /PRNewswire/ - DiagnoCure, Inc.
QUEBEC CITY, Jan. 13, 2014 /PRNewswire/ - DiagnoCure Inc.